Sklamberg Quoted in The Pink Sheet on FDA Reinstatement of UDI

Life Sciences & Healthcare Regulatory partner Howard Sklamberg was quoted in an article from The Pink Sheet, "US FDA's Unapproved Drugs Initiative Comes Back to Life, with New Enforcement Guidance on its Way." The article discusses the reinstatement of the Unapproved Drugs Initiative (UDI), the FDA's longstanding compliance policy program governing marketed, unapproved drugs.

» Read the full article (subscription required).